A Prospective, Multicenter Clinical Study of Percutaneous Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events in Patients With Atrial Fibrillation

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This clinical study is a prospective, multi-center, non-interventional study designed to investigate the safety and effectiveness of percutaneous LAA appendage closure by using LAmbre™ Left Atrial Appendage Occluder System. 579 patients with valvular AF complicated with previous AF-related embolic events (including ischemic stroke, TIA and systemic embolism) were enrolled at about 20 study sites nationwide. The baseline data, operation process and relevant follow-up information of subjects were recorded at 7 months after operation or before discharge and at 1, 3, 6, 12 and 24 months after operation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years, male or female;

• Patients who are able to understand the purpose of the study, voluntarily participate in and sign the informed consent form (ICF), and are willing to complete the follow-up as required by the protocol;

• Indications for left atrial appendage closure;

• Patients with non-valvular AF complicated with previous AF related embolic event and meeting one of the following conditions;

‣ HAS-BLED bleeding risk score ≥ 3 points;

⁃ Not suitable for long-term oral anticoagulant therapy;

⁃ Poor compliance with oral anticoagulants;

⁃ CHA2DS2-VASc score ≧ 2 points;

Locations
Other Locations
China
Qilu Hospital of Shandong University
RECRUITING
Jinan
Sichuan Mianyang 404 Hospital
RECRUITING
Mianyang
Shanghai Songjiang District Central Hospital
RECRUITING
Shanghai
The first Affiliated Hospital of WMU
RECRUITING
Wenzhou
The Second Affiliated Hospital and Yuying Children's Hospital of WMU
RECRUITING
Wenzhou
Contact Information
Primary
Chenyang Jiang, Doctor
panshangming@lifetechmed.com
8613857190051
Time Frame
Start Date: 2020-11-12
Estimated Completion Date: 2027-11
Participants
Target number of participants: 579
Related Therapeutic Areas
Sponsors
Leads: Lifetech Scientific (Shenzhen) Co., Ltd.

This content was sourced from clinicaltrials.gov